911.0500 -27.25 (-2.90%)
NSE Dec 26, 2025 15:31 PM
Volume: 223.9K
 

Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. is trading above all available SMAs
More from Strides Pharma Science Ltd.
Recommended